Clinical Trial Update: Pharmacokinetics, Safety and Tolerability of Different Formulations and Dose Strengths of Quarterly Risperidone (QUAR) in Patients With Schizophrenia [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update evaluating pharmacokinetics, safety, and tolerability of different formulations and dose strengths of Quarterly Risperidone (QUAR)…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Quarterly Risperidone (QUAR) (risperidone)

Snippet

Sponsor: Rovi Pharmaceuticals Laboratories | Conditions: Schizophrenia | Phase 1 | Status: COMPLETED